S&P 500   5,009.00 (-0.26%)
DOW   37,762.47 (+0.02%)
QQQ   423.84 (-0.47%)
AAPL   167.09 (-0.54%)
MSFT   404.86 (-1.69%)
META   502.20 (+1.62%)
GOOGL   156.29 (+0.53%)
AMZN   179.43 (-1.02%)
TSLA   150.55 (-3.15%)
NVDA   847.87 (+0.89%)
AMD   154.93 (+0.59%)
NIO   4.02 (+2.81%)
BABA   68.92 (+0.15%)
T   16.28 (+0.99%)
F   12.02 (-0.17%)
MU   112.43 (-3.35%)
GE   153.80 (-1.20%)
CGC   7.92 (+22.03%)
DIS   112.82 (-0.11%)
AMC   2.96 (-0.67%)
PFE   25.38 (-0.16%)
PYPL   62.22 (-1.64%)
XOM   118.40 (-0.19%)
S&P 500   5,009.00 (-0.26%)
DOW   37,762.47 (+0.02%)
QQQ   423.84 (-0.47%)
AAPL   167.09 (-0.54%)
MSFT   404.86 (-1.69%)
META   502.20 (+1.62%)
GOOGL   156.29 (+0.53%)
AMZN   179.43 (-1.02%)
TSLA   150.55 (-3.15%)
NVDA   847.87 (+0.89%)
AMD   154.93 (+0.59%)
NIO   4.02 (+2.81%)
BABA   68.92 (+0.15%)
T   16.28 (+0.99%)
F   12.02 (-0.17%)
MU   112.43 (-3.35%)
GE   153.80 (-1.20%)
CGC   7.92 (+22.03%)
DIS   112.82 (-0.11%)
AMC   2.96 (-0.67%)
PFE   25.38 (-0.16%)
PYPL   62.22 (-1.64%)
XOM   118.40 (-0.19%)
S&P 500   5,009.00 (-0.26%)
DOW   37,762.47 (+0.02%)
QQQ   423.84 (-0.47%)
AAPL   167.09 (-0.54%)
MSFT   404.86 (-1.69%)
META   502.20 (+1.62%)
GOOGL   156.29 (+0.53%)
AMZN   179.43 (-1.02%)
TSLA   150.55 (-3.15%)
NVDA   847.87 (+0.89%)
AMD   154.93 (+0.59%)
NIO   4.02 (+2.81%)
BABA   68.92 (+0.15%)
T   16.28 (+0.99%)
F   12.02 (-0.17%)
MU   112.43 (-3.35%)
GE   153.80 (-1.20%)
CGC   7.92 (+22.03%)
DIS   112.82 (-0.11%)
AMC   2.96 (-0.67%)
PFE   25.38 (-0.16%)
PYPL   62.22 (-1.64%)
XOM   118.40 (-0.19%)
S&P 500   5,009.00 (-0.26%)
DOW   37,762.47 (+0.02%)
QQQ   423.84 (-0.47%)
AAPL   167.09 (-0.54%)
MSFT   404.86 (-1.69%)
META   502.20 (+1.62%)
GOOGL   156.29 (+0.53%)
AMZN   179.43 (-1.02%)
TSLA   150.55 (-3.15%)
NVDA   847.87 (+0.89%)
AMD   154.93 (+0.59%)
NIO   4.02 (+2.81%)
BABA   68.92 (+0.15%)
T   16.28 (+0.99%)
F   12.02 (-0.17%)
MU   112.43 (-3.35%)
GE   153.80 (-1.20%)
CGC   7.92 (+22.03%)
DIS   112.82 (-0.11%)
AMC   2.96 (-0.67%)
PFE   25.38 (-0.16%)
PYPL   62.22 (-1.64%)
XOM   118.40 (-0.19%)

Compare Stocks

Comparative Price Performance Over Time

Compare Stocks - Price & Volume

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
AxoGen, Inc. stock logo
AXGN
AxoGen
$6.57
-5.3%
$8.74
$3.45
$10.83
$287.04M1.03416,688 shs136,050 shs
Natus Medical Incorporated stock logo
NTUS
Natus Medical
$32.96
$32.96
$20.90
$33.93
$1.14B0.22325,002 shs1,514 shs
TransMedics Group, Inc. stock logo
TMDX
TransMedics Group
$87.60
-0.3%
$83.01
$36.42
$99.63
$2.87B1.99686,890 shs555,556 shs
ViewRay, Inc. stock logo
VRAY
ViewRay
$0.34
$0.02
$4.96
$4.59M0.817.51 million shs108.50 million shs
The Best High-Yield Dividend Stocks for 2024 Cover

Looking to generate income with your stock portfolio? Use these ten stocks to generate a safe and reliable source of investment income.

Get This Free Report

Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
AxoGen, Inc. stock logo
AXGN
AxoGen
-0.86%-7.47%-9.99%-14.74%-29.54%
Natus Medical Incorporated stock logo
NTUS
Natus Medical
0.00%0.00%0.00%0.00%0.00%
TransMedics Group, Inc. stock logo
TMDX
TransMedics Group
-5.84%-8.14%+18.47%+9.46%+23.42%
ViewRay, Inc. stock logo
VRAY
ViewRay
0.00%0.00%0.00%0.00%-97.95%

MarketRank™

CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
AxoGen, Inc. stock logo
AXGN
AxoGen
1.7233 of 5 stars
3.53.00.00.00.02.50.6
Natus Medical Incorporated stock logo
NTUS
Natus Medical
N/AN/AN/AN/AN/AN/AN/AN/A
TransMedics Group, Inc. stock logo
TMDX
TransMedics Group
0.7969 of 5 stars
2.41.00.00.01.82.50.6
ViewRay, Inc. stock logo
VRAY
ViewRay
1.5559 of 5 stars
3.00.00.04.40.01.70.0

Analyst Ratings

CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
AxoGen, Inc. stock logo
AXGN
AxoGen
3.00
Buy$10.6762.35% Upside
Natus Medical Incorporated stock logo
NTUS
Natus Medical
N/AN/AN/AN/A
TransMedics Group, Inc. stock logo
TMDX
TransMedics Group
2.86
Moderate Buy$102.0016.44% Upside
ViewRay, Inc. stock logo
VRAY
ViewRay
2.00
Hold$1.33∞ Upside

Current Analyst Ratings

Latest VRAY, AXGN, NTUS, and TMDX Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
3/28/2024
TransMedics Group, Inc. stock logo
TMDX
TransMedics Group
Piper Sandler
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageOverweight$95.00
2/28/2024
TransMedics Group, Inc. stock logo
TMDX
TransMedics Group
Morgan Stanley
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetEqual Weight ➝ Equal Weight$75.00 ➝ $95.00
2/27/2024
TransMedics Group, Inc. stock logo
TMDX
TransMedics Group
JPMorgan Chase & Co.
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetOverweight ➝ Overweight$87.00 ➝ $105.00
2/27/2024
TransMedics Group, Inc. stock logo
TMDX
TransMedics Group
Oppenheimer
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetOutperform ➝ Outperform$92.00 ➝ $105.00
1/19/2024
AxoGen, Inc. stock logo
AXGN
AxoGen
Cantor Fitzgerald
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOverweight ➝ Overweight$12.00
(Data available from 4/18/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Sales & Book Value

CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
AxoGen, Inc. stock logo
AXGN
AxoGen
$159.01M1.81N/AN/A$2.22 per share2.96
Natus Medical Incorporated stock logo
NTUS
Natus Medical
$473.44M2.41$2.02 per share16.34$12.44 per share2.65
TransMedics Group, Inc. stock logo
TMDX
TransMedics Group
$241.62M11.86$0.13 per share655.55$4.20 per share20.86
ViewRay, Inc. stock logo
VRAY
ViewRay
$105.86M0.00N/AN/A$0.45 per share0.00

Profitability & Earnings

CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
AxoGen, Inc. stock logo
AXGN
AxoGen
-$21.72M-$0.52N/AN/AN/A-13.66%-22.38%-11.24%5/2/2024 (Confirmed)
Natus Medical Incorporated stock logo
NTUS
Natus Medical
$13.18M$0.3789.0820.99N/A2.65%10.15%7.65%N/A
TransMedics Group, Inc. stock logo
TMDX
TransMedics Group
-$25.03M-$0.77N/A213.66N/A-10.36%-2.35%-0.60%4/30/2024 (Confirmed)
ViewRay, Inc. stock logo
VRAY
ViewRay
-$107.33M-$0.60N/AN/AN/A-104.30%-120.48%-42.39%N/A

Latest VRAY, AXGN, NTUS, and TMDX Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/2/2024N/A
AxoGen, Inc. stock logo
AXGN
AxoGen
-$0.10N/A+$0.10N/AN/AN/A  
4/30/2024N/A
TransMedics Group, Inc. stock logo
TMDX
TransMedics Group
-$0.05N/A+$0.05N/AN/AN/A  
3/5/2024Q4 2023
AxoGen, Inc. stock logo
AXGN
AxoGen
-$0.20-$0.09+$0.11-$0.09$42.70 million$42.92 million
2/26/2024Q4 2023
TransMedics Group, Inc. stock logo
TMDX
TransMedics Group
-$0.10$0.12+$0.22$0.12$68.49 million$81.20 million    

Dividends

CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
AxoGen, Inc. stock logo
AXGN
AxoGen
N/AN/AN/AN/AN/A
Natus Medical Incorporated stock logo
NTUS
Natus Medical
N/AN/AN/AN/AN/A
TransMedics Group, Inc. stock logo
TMDX
TransMedics Group
N/AN/AN/AN/AN/A
ViewRay, Inc. stock logo
VRAY
ViewRay
N/AN/AN/AN/AN/A

Debt

CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
AxoGen, Inc. stock logo
AXGN
AxoGen
0.71
2.89
2.14
Natus Medical Incorporated stock logo
NTUS
Natus Medical
N/A
2.54
1.90
TransMedics Group, Inc. stock logo
TMDX
TransMedics Group
3.69
9.30
8.49
ViewRay, Inc. stock logo
VRAY
ViewRay
N/A
1.16
0.91

Ownership

Institutional Ownership

CompanyInstitutional Ownership
AxoGen, Inc. stock logo
AXGN
AxoGen
80.29%
Natus Medical Incorporated stock logo
NTUS
Natus Medical
92.35%
TransMedics Group, Inc. stock logo
TMDX
TransMedics Group
99.67%
ViewRay, Inc. stock logo
VRAY
ViewRay
92.97%

Insider Ownership

CompanyInsider Ownership
AxoGen, Inc. stock logo
AXGN
AxoGen
7.21%
Natus Medical Incorporated stock logo
NTUS
Natus Medical
1.20%
TransMedics Group, Inc. stock logo
TMDX
TransMedics Group
6.70%
ViewRay, Inc. stock logo
VRAY
ViewRay
2.50%

Miscellaneous

CompanyEmployeesShares OutstandingFree FloatOptionable
AxoGen, Inc. stock logo
AXGN
AxoGen
42643.69 million40.54 millionOptionable
Natus Medical Incorporated stock logo
NTUS
Natus Medical
1,40034.58 million34.17 millionOptionable
TransMedics Group, Inc. stock logo
TMDX
TransMedics Group
58432.71 million30.52 millionOptionable
ViewRay, Inc. stock logo
VRAY
ViewRay
295183.40 million178.82 millionOptionable

VRAY, AXGN, NTUS, and TMDX Headlines

SourceHeadline
The best 4K Blu-ray players for 2024The best 4K Blu-ray players for 2024
digitaltrends.com - March 24 at 6:22 PM
VRAY Jan 2025 2.000 callVRAY Jan 2025 2.000 call
finance.yahoo.com - March 16 at 9:28 AM
VRAY Jan 2025 0.500 putVRAY Jan 2025 0.500 put
finance.yahoo.com - March 16 at 9:28 AM
VRAY Jan 2025 0.500 callVRAY Jan 2025 0.500 call
finance.yahoo.com - March 16 at 12:50 AM
VRAY Jan 2025 3.000 putVRAY Jan 2025 3.000 put
finance.yahoo.com - March 16 at 12:50 AM
Creating the Scene with V-Ray for 3ds MaxCreating the Scene with V-Ray for 3ds Max
archdaily.com - March 2 at 1:34 PM
How to Supercharge Your SketchUp Renders With V-Ray Lights and MaterialsHow to Supercharge Your SketchUp Renders With V-Ray Lights and Materials
archdaily.com - February 26 at 6:18 PM
ViewRay Inc VRAYQViewRay Inc VRAYQ
morningstar.com - November 4 at 7:06 AM
NUBURU Appoints Brian Knaley as new CEONUBURU Appoints Brian Knaley as new CEO
benzinga.com - November 1 at 5:27 PM
Open Letter to ViewRay Customers, Service, Software Engineers and Suppliers-Lets Preserve ViewRay TechnologyOpen Letter to ViewRay Customers, Service, Software Engineers and Suppliers-Let's Preserve ViewRay Technology
tmcnet.com - October 19 at 8:02 AM
Letter to ViewRay Lenders/Investment Bankers and Customers From Krishnan Suthanthiran, President/Founder of TeamBest Global CompaniesLetter to ViewRay Lenders/Investment Bankers and Customers From Krishnan Suthanthiran, President/Founder of TeamBest Global Companies
benzinga.com - October 17 at 1:37 PM
ViewRay Inc (6L9.BE)ViewRay Inc (6L9.BE)
ca.finance.yahoo.com - August 20 at 6:13 PM
B. Riley Securities downgrades ViewRay Inc. (VRAY) rating to a NeutralB. Riley Securities downgrades ViewRay Inc. (VRAY) rating to a Neutral
knoxdaily.com - July 24 at 3:24 PM
ViewRay stock to be delisted from Nasdaq and moved to OTC ExchangeViewRay stock to be delisted from Nasdaq and moved to OTC Exchange
seekingalpha.com - July 21 at 6:20 PM
ViewRay® Announces Commencement of Nasdaq Delisting Proceedings: Common Stock Expected to Begin Trading on the OTC MarketsViewRay® Announces Commencement of Nasdaq Delisting Proceedings: Common Stock Expected to Begin Trading on the OTC Markets
finance.yahoo.com - July 21 at 6:20 PM
Keeping an Eye on ViewRay Inc. (VRAY) After Insider Trading ActivityKeeping an Eye on ViewRay Inc. (VRAY) After Insider Trading Activity
knoxdaily.com - July 19 at 1:18 PM
Why ViewRay Stock Hit A New 52-Week Low TodayWhy ViewRay Stock Hit A New 52-Week Low Today
benzinga.com - July 18 at 8:33 PM
ViewRay, Inc.: ViewRay Files Voluntary Chapter 11 PetitionsViewRay, Inc.: ViewRay Files Voluntary Chapter 11 Petitions
finanznachrichten.de - July 18 at 10:32 AM
Why ViewRay (VRAY) Stock Hit A New 52-Week Low TodayWhy ViewRay (VRAY) Stock Hit A New 52-Week Low Today
msn.com - July 17 at 1:15 PM
Why Is ViewRay (VRAY) Stock Down 69% Today?Why Is ViewRay (VRAY) Stock Down 69% Today?
investorplace.com - July 17 at 12:04 PM
ViewRay® Files Voluntary Chapter 11 PetitionsViewRay® Files Voluntary Chapter 11 Petitions
finance.yahoo.com - July 17 at 8:15 AM
ViewRay Inc. (VRAY) may enjoy gains as insiders got busy in the recent daysViewRay Inc. (VRAY) may enjoy gains as insiders got busy in the recent days
knoxdaily.com - July 12 at 5:59 PM
ViewRay: Near-Term Bankruptcy Filing Might Be In The Cards - SellViewRay: Near-Term Bankruptcy Filing Might Be In The Cards - Sell
msn.com - July 7 at 9:16 AM
Analyzing ViewRay Inc. (VRAY) After Recent Trading ActivityAnalyzing ViewRay Inc. (VRAY) After Recent Trading Activity
knoxdaily.com - July 5 at 8:52 PM

New MarketBeat Followers Over Time

Media Sentiment Over Time

Company Descriptions

AxoGen logo

AxoGen

NASDAQ:AXGN
AxoGen, Inc., together with its subsidiaries, develops and commercializes technologies for peripheral nerve regeneration and repair worldwide. The company's products include Avance Nerve Graft, a biologically active off-the-shelf processed human nerve allograft for bridging severed peripheral nerves without the comorbidities associated with a second surgical site; AxoGuard Nerve Connector, a porcine submucosa extracellular matrix (ECM) coaptation aid for tensionless repair of severed peripheral nerves; AxoGuard Nerve Protector, a porcine submucosa ECM product that is used to wrap and protect damaged peripheral nerves, as well as reinforces the nerve reconstruction while preventing soft tissue attachments; and Axoguard HA+ Nerve Protector, a processed porcine submucosa ECM base layer with a hyaluronate-alginate gel coating designed to provide short- and long-term protection for peripheral nerve injuries. Its products also comprise Axoguard Nerve Cap, a porcine submucosa ECM product that is used to protect a peripheral nerve end, as well as separates the nerve from the surrounding environment to reduce the development of symptomatic or painful neuroma; and AxoTouch two-point discriminator, a tool that is used for measuring the innervation density of surface area of the skin. The company provides its products to hospitals, surgery centers, and military hospitals, plastic reconstructive surgeons, orthopedic and plastic hand surgeons, and various oral and maxillofacial surgeons. AxoGen, Inc. is headquartered in Alachua, Florida.
Natus Medical logo

Natus Medical

NASDAQ:NTUS
Natus Medical Incorporated provides medical device solutions focuses on the diagnosis and treatment of patients with central nervous and sensory system disorders worldwide. It offers products and technologies used for the screening, detection, treatment, monitoring, and tracking of common medical ailments in newborn care, hearing impairment, neurological and neurosurgical treatments, epilepsy, sleep disorders, and neuromuscular diseases. The company also provides computerized neurodiagnostic systems for audiology, neurology, polysomnography, and neonatology; and software systems for managing and tracking disorders and diseases for public health laboratories. In addition, it offers electroencephalography, long term monitoring, intensive care unit monitoring, electromyography, sleep analysis or polysomnography, and intra-operative monitoring solutions. Further, the company provides hearing assessment, screening, and instrument fitting solutions; jaundice management products; brain injury products; and eye imaging systems and products used in the advanced science and practice of neonatal and pediatric retinal imaging. Additionally, it offers essential products used in the everyday operation of neonatal intensive care unit (NICU); balance assessment systems to evaluate patients with balance disorders; and NICVIEW, a live streaming video for families with babies in the NICU. The company also provides computer-based audiological, otoneurologic, and vestibular instrumentation for hearing and balance care professionals. It serves university medical centers, public and private hospitals, physician offices, clinics, research laboratories, and others. The company was formerly known as ALGOTEK Instruments, Inc. and changed its name to Natus Medical Incorporated in September 1988. Natus Medical Incorporated was incorporated in 1987 and is headquartered in Middleton, Wisconsin.
TransMedics Group logo

TransMedics Group

NASDAQ:TMDX
TransMedics Group, Inc., a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body. Its OCS includes OCS LUNG for the preservation of standard criteria donor lungs for double-lung transplantation; OCS Heart, a technology for preservation of DBD donor hearts deemed unsuitable due to limitations of cold storage and for ex vivo reanimation, functional monitoring, and beating-heart preservation of donation-after-circulatory-death hearts; and OCS Liver for the preservation of DBD and DCD of donor livers. The company also developed national OCS program, a turnkey solution for outsourced organ retrieval; and provides OCS organ management and logistics services, including aviation and ground transportation, and other coordination activity. The company was founded in 1998 and is headquartered in Andover, Massachusetts.
ViewRay logo

ViewRay

NASDAQ:VRAY
ViewRay, Inc. designs, manufactures, and markets magnetic resonance imaging (MRI) guided radiation therapy systems to image and treat cancer patients in the United States, Italy, France, Taiwan, the United Kingdom, and internationally. It provides MRIdian, which is an MRI guided radiation therapy system that addresses beam distortion, skin toxicity, and other concerns. The company serves university research and teaching hospitals, community hospitals, private practices, government institutions, and freestanding cancer centers through a network of direct sales force and distributors. ViewRay, Inc. was founded in 2004 and is headquartered in Denver, Colorado.